For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Edwards Lifesciences Corp’s stock clocked out at $81.83, up 0.83% from its previous closing price of $81.16. In other words, the price has increased by $0.83 from its previous closing price. On the day, 2.83 million shares were traded. EW stock price reached its highest trading level at $81.835 during the session, while it also had its lowest trading level at $80.37.
Ratios:
To gain a deeper understanding of EW’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.82 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 81.72. For the most recent quarter (mrq), Quick Ratio is recorded 3.87 and its Current Ratio is at 4.68. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 24, 2025, Piper Sandler Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $80.
Stifel Upgraded its Hold to Buy on January 30, 2025, whereas the target price for the stock was revised from $75 to $90.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 18 ’25 when Wood Larry L sold 8,950 shares for $78.06 per share. The transaction valued at 698,679 led to the insider holds 206,900 shares of the business.
Wood Larry L bought 8,950 shares of EW for $698,679 on Aug 18 ’25. On Jul 28 ’25, another insider, Lippis Daniel J., who serves as the CVP, JAPAC of the company, sold 4,114 shares for $79.46 each. As a result, the insider received 326,900 and left with 22,002 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EW now has a Market Capitalization of 48042397696 and an Enterprise Value of 44743991296. As of this moment, Edwards’s Price-to-Earnings (P/E) ratio for their current fiscal year is 55.86, and their Forward P/E ratio for the next fiscal year is 29.31. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 6.21. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.45 while its Price-to-Book (P/B) ratio in mrq is 4.56. Its current Enterprise Value per Revenue stands at 7.87 whereas that against EBITDA is 25.703.
Stock Price History:
The Beta on a monthly basis for EW is 1.07, which has changed by 0.19025457 over the last 52 weeks, in comparison to a change of 0.1513431 over the same period for the S&P500. Over the past 52 weeks, EW has reached a high of $83.00, while it has fallen to a 52-week low of $64.00. The 50-Day Moving Average of the stock is 5.45%, while the 200-Day Moving Average is calculated to be 11.07%.
Shares Statistics:
It appears that EW traded 4.27M shares on average per day over the past three months and 4015090 shares per day over the past ten days. A total of 587.90M shares are outstanding, with a floating share count of 575.03M. Insiders hold about 2.06% of the company’s shares, while institutions hold 86.81% stake in the company. Shares short for EW as of 1753920000 were 7999420 with a Short Ratio of 1.87, compared to 1751241600 on 7209698. Therefore, it implies a Short% of Shares Outstanding of 7999420 and a Short% of Float of 1.55.
Earnings Estimates
The firm’s stock currently is rated by 26.0 analysts. The consensus estimate for the next quarter is $0.61, with high estimates of $0.7 and low estimates of $0.56.
Analysts are recommending an EPS of between $2.55 and $2.41 for the fiscal current year, implying an average EPS of $2.5. EPS for the following year is $2.79, with 31.0 analysts recommending between $2.93 and $2.66.
Revenue Estimates
In the current quarter, 27 analysts expect revenue to total $1.49B. It ranges from a high estimate of $1.52B to a low estimate of $1.46B. As of the current estimate, Edwards Lifesciences Corp’s year-ago sales were $1.35BFor the next quarter, 27 analysts are estimating revenue of $1.54B. There is a high estimate of $1.6B for the next quarter, whereas the lowest estimate is $1.52B.
A total of 32 analysts have provided revenue estimates for EW’s current fiscal year. The highest revenue estimate was $6.04B, while the lowest revenue estimate was $5.81B, resulting in an average revenue estimate of $5.97B. In the same quarter a year ago, actual revenue was $5.44BBased on 31 analysts’ estimates, the company’s revenue will be $6.55B in the next fiscal year. The high estimate is $6.74B and the low estimate is $6.28B.
